The epidemiology of pan/extreme drug resistance

Antibiotic Policies: Controlling Hospital Acquired Infection

Volumn 9781441917348, Issue , 2012, Pages 27-38

  Hayashi, Yoshiro ^a,b   Paterson, David L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotic combinations; Antibiotic resistance; Carbapenemases; Colistin; PDR; Tigecycline

Indexed keywords

EID: 84930022313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-1734-8_3     Document Type: Chapter

References (35)

1. Tseng S-P, Tsai J-C, Teng L-J, Hsueh P-R. Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan. Journal of Antimicrobial Chemotherapy 2009;64(6):1170-4.
2. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-ß-lactamase NDM-1-producing multidrug resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010:54(11):4914-6.
3. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Aci-netobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009 Aug;15(8):1325-7.
4. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acineto-bacter baumannii. Emerg Infect Dis 2009;15(6):980-2.
5. Grosso F, Quinteira S, Peixe L. Emergence of an extreme-drug-resistant (XDR) Acinetobacter baumannii carrying blaOXA-23 in a patient with acute necrohaemorrhagic pancreatitis. Journal of Hospital Infection 2010;75(1):82-3.
6. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resis-tant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients. International Journal of Antimicrobial Agents 2008;32(5):450-4.
7. Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneu-moniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimi-crob Chemother 2007;59(4):786-90.
8. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection. J Clin Microbiol 2009;47(5):1611-2.
9. Samonis G, Matthaiou Dimitrios K, Kofteridis D, Maraki S, Falagas Matthew E. In Vitro Susceptibility to Various Antibiotics of Colistin Resistant Gram Negative Bacterial Isolates in a General Tertiary Hospital in Crete, Greece. Clinical Infectious Diseases 2010;50(12):1689-91.
10. Tóth Á, Damjanova I, Puskás E, et al. Emergence of a colistin-resistant KPC-2-producing Kleb-siella pneumoniae ST258 clone in Hungary. European Journal of Clinical Microbiology & Infectious Diseases 2010;29(7):765-9.
11. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009 15;49(2):271-4.
12. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases 2010;10(9):597-602.
13. Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Gomez M, Lopez F. Antimicrobial resistance surveillance: VIRA STUDY 2006. Enferm Infecc Microbiol Clin 2006;24(10):617-28.
14. Korten V, Ulusoy S, Zarakolu P, Mete B. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagnostic Microbiology and Infectious Disease 2007;59(4):453-7.
15. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagnostic Microbiology and Infectious Disease 2009;65(3):288-99.
16. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. International Journal of Antimicrobial Agents 2009;34(6):585-8.
17. Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009;34(2):121-30.
18. WHONET Greece. http://www.mednet.gr/whonet/.
19. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010;60(6):440-51.
20. Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. International Journal of Antimicrobial Agents 2010;35(3):227-34.
21. Hsueh P-R, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). International Journal of Antimicrobial Agents 2010;36(5):408-14.
22. Bantar C, Curcio D, Fernandez Canigia L, Garcia P, Guzman Blanco M, Leal AL. Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother 2009;21(2):144-52.
23. Reinert RR, Low DE, Rossi Fv, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. Journal of Antimicrobial Chemotherapy 2007;60(5):1018-29.
24. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clinical Therapeutics 2008;30(11):2040-50.
25. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagnostic Microbiology and Infectious Disease 2008;61(2):203-13.
26. Yamaguchi K, Ohno A, Ishii Y, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12, 919 clinical isolates obtained from 72 centers in 2007. Jpn J Antibiot 2009;62(4):346-70.
27. Jean SS, Hsueh PR, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009;33(3):266-71.
28. Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 2010 Sep;68(1):73-9.
29. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, the SIWG. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J Med Microbiol 2010;59(9):1050-4.
30. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas ae-ruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl. 2:S43-48.
31. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45(9):1179-81.
32. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008: 46(7): 1121-22.
33. Europe Centre for Disease Prevention and Control (ECDC). Multi drug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance.
34. European Centre for Disease Prevention and Control (ECDC). http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/table-reports.aspx
35. Kumarasamy KK. Lancet Infectious Diseases 2010;10(9):597-602.